Thus, establishing the exact mechanism of benefit is key to understanding the benefits of SGLT2 inhibition and may also open up new and unexplored pathways which could provide rich avenues of understanding for the pathophysiology and potential future novel treatments of heart failure. Here, SLC5A2 is linked to heart failure.